Skip to main content

Table 2 Adverse events

From: Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

 

ALL Patients (n = 30)

Total

Grade3/4/5

All adverse events

 Any event

30 (100)

21 (70)

 Hepatotoxicity

  

  high ALT

4 (13)

2 (7)

 Gastrointestinal Disorders

  nausea

21 (70)

1 (3)

  vomiting

14 (47)

0

  diarrhea

23 (77)

3 (10)

   C. difficile colitis

1 (3)

1 (3)

 Electrolyte

      hypophosphatemia

4 (13)

2 (7)

     hypokalemia

6 (20)

1 (3)

      hypomagnesemia

8 (27)

1 (3)

 Hematological

  anemia

4 (13)

2 (7)

  febrile neutropenia

2 (7)

2 (7)

  neutropenia

8 (27)

5 (17)

  thrombocytopenia

6 (20)

3 (10)

 Nervous System

  seizure

2 (7)

1 (3)

  vasovagal reaction

1 (3)

1 (3)

 Infection

  

  pneumonia

1 (3)

1 (3)

 Constitutional

  fatigue

17 (57)

2 (7)

 Vascular Disorder

  pulmonary embolism

1 (3)

1 (3)

Immune-related adverse events

  

 Any event

26 (87)

4 (13)

 Gastrointestinal Disorders

  diarrhea

11 (37)

2 (7)

  vomiting

6 (20)

0

  autoimmune colitis

1 (3)

1 (3)

 Endocrine

  hypothyroidism

1 (3)

0

  pituitary disorder

1 (3)

0

 Skin Disorders

  rash

7 (23)

0

  pruritus

9 (30)

0

  urticaria

1 (3)

0

  vitiligo

1 (3)

0

  erythroderma

1 (3)

0

 Constitutional

  fatigue

11 (37)

1 (3)